- Recruiting
NCT03590652: Phase 2 - Daratumumab, Ixazomib, Pomalidomide + Dex as Salvage Therapy Refractory MM
Updated: Sep 24, 2022
The purpose of this study is to determine the overall response rate of patients with Multiple Myeloma to the combination of Daratumumab, Ixazomib, Pomalidomide and Dexamethasone.
The purpose of this study is to determine the overall response rate of patients with Multiple Myeloma to the combination of Daratumumab, Ixazomib, Pomalidomide and Dexamethasone.
Sponsor
University of California, San Diego
Collaborators
ClinicalTrials.gov Identifier: NCT03590652
Official Title: Phase II Study of the Combination of Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone as Salvage Therapy in Relapsed/Refractory Multiple Myeloma A University of California Hematologic Malignancies Consortium Protocol (UCHMC1809)
First Posted : July 18, 2018
Click here for details on ClinicalTrials.gov
Daratumumab : National Cancer Institute
Daratumumab : MedlinePlus Drug Information
Dexamethasone : National Cancer Institute
Dexamethasone : MedlinePlus Drug Information
Ixazomib: National Cancer Institute
Ixazomib: MedlinePlus Drug Information
Pomalidomide: National Cancer Institute
Pomalidomide: MedlinePlus Drug Information
Locations
United States, California
UCSD Health - University of Clifornia San Diego - Moores Cancer Center
https://clinicaltrials.ucsd.edu/multiple-myeloma
https://health.ucsd.edu/Pages/default.aspx